Xenon Pharmaceuticals Inc. (XENE) Stock Price & How to Invest

Last updated November 2026

Short answer

Xenon Pharmaceuticals (XENE) is a clinical-stage neuroscience company whose whole story rides on azetukalner, a first-in-class KV7 potassium channel opener that posted positive Phase 3 data in focal epilepsy and was submitted to the FDA in September 2026. In the same month Xenon paused two late-stage psychiatry trials to review tolerability, and as of November 20, 2026 the shares closed near $37.23, down about 16% year to date and about 38% over three months (though up about 5% in the past month), for a market cap of roughly $3.7 billion. Investing in XENE means underwriting a pre-revenue drug developer with a large cash cushion but no approved product yet.

XENE stock price

As of 2026-11-20, Xenon Pharmaceuticals Inc. (XENE) last closed at $37.04, down 10.0% over the past year. Over the past 52 weeks it has traded between $33.49 and $70.96.

XENE last close
$37.04
1 day
-1.38%
1 month
+3.03%
1 year
-10.01%
52-week range
$33.49 to $70.96
Last close
2026-11-20

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Xenon Pharmaceuticals Inc.'s investor relations page. Walnut is informational, not investment advice.

XENE key stats

At $37.04 on November 20, 2026, Xenon Pharmaceuticals Inc. (XENE) has a market cap of $3.6B.

Market cap
$3.6B
Price to book
3.2
Beta
0.08

Market cap, P/E and yield are measured at the $37.04 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Xenon Pharmaceuticals Inc. (XENE)?

The last two weeks for Xenon Pharmaceuticals Inc., as of November 22, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • XENE closed at $37.04 on November 20, 2026, down 8.5% over the past five trading days (from $40.48).
  • On November 9, 2026, Xenon Pharmaceuticals Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 9, 2026, Xenon Pharmaceuticals Inc. filed an 8-K with the SEC reporting quarterly results and information shared with investors (Regulation FD) (Item 2.02, Item 7.01). Read the 8-K on sec.gov
  • On November 17, 2026, JP Morgan lowered its target to $80.00 from $82.00 (Overweight).

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does Xenon Pharmaceuticals Inc. (XENE) do?

Xenon Pharmaceuticals is a Burnaby, Canada based, US-listed neuroscience biotech developing treatments for epilepsy and neuropsychiatric conditions. Its lead asset is azetukalner (formerly XEN1101), a potent KV7 potassium channel opener that, if approved, would be the only channel opener of its kind among antiseizure medications. The company is running a broad Phase 3 program spanning focal onset seizures, primary generalized tonic-clonic seizures, and neuropsychiatric indications including major depressive disorder and bipolar depression.

The investment picture is classic late-stage biotech. In March 2026 Xenon reported positive topline Phase 3 X-TOLE2 data in focal onset seizures, with the high dose cutting monthly seizure frequency by roughly 53% from baseline, and in September 2026 the company submitted its New Drug Application for focal onset seizures, built on the X-TOLE and X-TOLE2 studies; Xenon is modeling a standard review of about 12 months, with possible DEA scheduling adding roughly three months after any approval. The same month brought a setback on the psychiatry side: after discussion with the data safety monitoring board, Xenon paused the X-NOVA3 (major depressive disorder) and X-CEED (bipolar depression) studies to assess whether a different dose escalation could improve tolerability, citing dizziness, somnolence and less common neuropsychiatric effects. The X-NOVA2 depression study continues, with data expected in the first quarter of 2027, and the company said the epilepsy program is unchanged. An equity raise earlier in 2026 lifted cash and marketable securities to about $1.34 billion, which management said funds operations into 2029. Third-quarter 2026 results showed a net loss of about $110 million, or $1.11 per share, slightly narrower than the roughly $1.15 analysts expected, taking the trailing net loss to about $429 million. The stock has fallen hard on the news flow: as of November 20, 2026 XENE closed near $37.23, down about 38% over three months and about 16% year to date, a little above its 52-week low of $33.38, for a market cap near $3.7 billion. There is no meaningful revenue yet, so the stock trades on clinical readouts, the FDA path, and the eventual commercial reception of azetukalner rather than on current earnings.

What's driving Xenon Pharmaceuticals Inc. (XENE)?

1. Azetukalner FDA filing and launch

The central catalyst is FDA review of azetukalner in focal onset seizures: Xenon submitted its NDA in September 2026, built on X-TOLE2 data that the company describes as the highest placebo-adjusted efficacy observed in a registration-stage epilepsy study, and is modeling a standard review of about 12 months, which would point to a decision around September 2027 if the review runs its full course. Approval would give Xenon its first commercial product and a differentiated KV7 mechanism. An October 2026 note from RBC argued the approval path is unlikely to be hurt by the tolerability issues seen in psychiatry. The commercial ramp against entrenched generics and branded antiseizure drugs is the swing factor for the long-term thesis.

2. Pipeline breadth beyond focal epilepsy

Azetukalner is also in Phase 3 for primary generalized tonic-clonic seizures and in development for major depressive disorder and bipolar depression. The psychiatry leg took a hit in September 2026, when Xenon paused X-NOVA3 and X-CEED to rework dose escalation for tolerability; X-NOVA2, more than 80% enrolled, continues toward a first-quarter 2027 readout. Positive neuropsychiatry data would still reframe the company as a multi-indication franchise, but the pause has made that option look less certain to the market.

3. Balance-sheet runway

An $837.6 million equity raise earlier in 2026 pushed cash and marketable securities to roughly $1.34 billion, which management said funds operations into 2029. Losses continue (about $110 million in the third quarter of 2026 and about $429 million over the trailing year), and Yahoo Finance's cash line at September 30, 2026, which may not capture longer-dated securities, shows about $951 million against about $6 million of debt; trailing operating cash outflow was about $356 million. That cushion lets Xenon carry the NDA review, ongoing Phase 3 trials, and an early commercial build without an immediate need to raise again. Insiders bought more than $1.6 million of stock in late September 2026.

What are the risks to Xenon Pharmaceuticals Inc. (XENE)?

Xenon has no approved product and no meaningful revenue, so the entire valuation rests on azetukalner clearing FDA review and selling once launched. Clinical-stage biotech carries binary risk: a review delay, a complete response letter, or disappointing data in the generalized seizure or neuropsychiatric programs could sharply reset the stock, and the September 2026 pause of two psychiatry trials over dizziness, somnolence and neuropsychiatric side effects shows how tolerability questions can spill onto the shares. Even with approval, azetukalner would enter a crowded antiseizure market with established generics and branded competitors, and a likely DEA scheduling step could delay launch. The company continues to post large net losses (about $110 million in Q3 2026), and while it has said its cash runway extends into 2029, further dilution is possible if programs expand or slip. The shares are volatile and sensitive to single data points: they fell about 38% in the three months to November 20, 2026, and traded between roughly $33.38 and $72.66 over the past 52 weeks.

What is the Xenon Pharmaceuticals Inc. (XENE) forecast?

16 analysts publish price targets on XENE, averaging $71.56 as of November 2026, or +93.2% against the $37.04 share price on November 20, 2026. The published targets run from $46.00 to $90.00, a moderate spread, and the ratings split 17 buy, 1 hold, 0 sell. Over the last six months there has been 1 raise and 8 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full XENE forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is XENE a buy or a sell?

We give no verdict on Xenon Pharmaceuticals Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Azetukalner FDA filing and launch. The central catalyst is FDA review of azetukalner in focal onset seizures: Xenon submitted its NDA in September 2026, built on X-TOLE2 data that the company describes as the highest placebo-adjusted efficacy observed in a registration-stage epilepsy study, and is modeling a standard review of about 12 months, which would point to a decision around September 2027 if the review runs its full course. The most optimistic published target, $90.00, assumes this works close to its best case.

The case against. Xenon has no approved product and no meaningful revenue, so the entire valuation rests on azetukalner clearing FDA review and selling once launched. The most pessimistic target, $46.00, is roughly what XENE is worth if this bites instead.

Read the full bull and bear case on XENE, including what would have to change to break either one. Walnut is not an investment adviser.

Has Xenon Pharmaceuticals Inc. (XENE) split its stock?

No. Xenon Pharmaceuticals Inc. (XENE) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Xenon Pharmaceuticals Inc. (XENE) valued?

Market cap, P/E and dividend yield at today's price are in the XENE key stats above. The business figures below come from Xenon Pharmaceuticals Inc.'s reported results as of November 2026 and change when it next reports.

  • Product revenue: ~$0 (pre-commercial)
  • Net loss (Q3 2026): ~$110M (EPS -$1.11 vs ~-$1.15 est.)
  • Net loss (TTM): ~$429M
  • Cash: ~$951M on Yahoo's cash line (Sept 30, 2026); ~$1.34B cash and securities reported after the 2026 raise

As of November 2026: Xenon trades as a pre-revenue biotech, so traditional multiples like price-to-earnings do not apply, and the roughly $3.7 billion market cap (down from about $5 billion in June) reflects reduced expectations for azetukalner after the September psychiatry trial pause rather than any change in current financials. The company burns cash by design to fund Phase 3 trials and a commercial build, offset by a large cash position that management has said funds operations into 2029. Consensus calls for a 2026 loss of about $4.56 per share and a 2027 loss of about $4.67, and the 16 analysts tracked by Yahoo Finance had a mean price target near $72; valuation moves with clinical and regulatory milestones far more than with quarterly results.

Who competes with Xenon Pharmaceuticals Inc. (XENE)?

Branded antiseizure drugs

Azetukalner would compete with newer branded focal-epilepsy therapies such as SK Life Science and Angelini Pharma's cenobamate (Xcopri) and UCB's Briviact and Vimpat. These carry established prescriber relationships and real-world data, so azetukalner's novel KV7 mechanism and efficacy profile are the wedge it must use to win share.

Generic and legacy epilepsy medications

The bulk of epilepsy prescriptions run through low-cost generics like levetiracetam, lamotrigine, and older sodium-channel and GABAergic agents. This large, cheap base is the pricing and access backdrop any new branded antiseizure drug faces, and it shapes how quickly a novel therapy can be adopted.

Neuroscience biotech peers

As a clinical-stage CNS developer, Xenon competes for investor capital and pipeline attention with other neuroscience and epilepsy-focused biotechs advancing novel mechanisms. Its differentiator is being the most advanced KV7 potassium channel opener, plus optionality in depression and bipolar indications.

What stocks are similar to Xenon Pharmaceuticals Inc. (XENE)?

Other names that sit close to XENE: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Xenon Pharmaceuticals Inc. (XENE)

There are three common ways to get XENE exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so XENE sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where XENE fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Xenon Pharmaceuticals Inc. (XENE)

XENE is a binary, pipeline-driven biotech bet on azetukalner reaching the market in epilepsy, now under FDA review, backed by a deep balance sheet (Yahoo Finance shows about $951 million of cash at September 30, 2026) but carrying the usual clinical and regulatory risk of a company with no product revenue, plus fresh doubt about the psychiatry indications.

More on Xenon Pharmaceuticals Inc. (XENE)

Whether XENE is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is XENE a buy or a sell?, and where the stock could go from here in the XENE stock forecast.

For income investors, whether XENE pays a dividend and how the payout looks is covered in does XENE pay a dividend? And to weigh XENE against a peer, read the full side-by-side comparisons: XENE vs UCB and XENE vs CNS.

Wondering how XENE fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Xenon Pharmaceuticals Inc.

Ask Walnut's AI anything about XENE and see how it fits what you own.

FAQ

What does Xenon Pharmaceuticals do?

+

Xenon is a clinical-stage neuroscience company developing treatments for epilepsy and neuropsychiatric disorders. Its lead drug, azetukalner, is a KV7 potassium channel opener in Phase 3 trials for focal and generalized seizures, major depressive disorder, and bipolar depression.

Is XENE a good investment?

+

That depends on your own goals and risk tolerance, and Walnut is not an investment adviser. XENE is a pre-revenue biotech whose value rests almost entirely on azetukalner reaching the market, which carries meaningful clinical, regulatory, and commercial risk alongside a strong cash position. As of November 20, 2026 the shares sit near $37.23, about 38% lower than three months earlier after the psychiatry trial pause and a little above their 52-week low.

Does Xenon have any approved products?

+

No. As of November 2026 Xenon has no approved product and no meaningful product revenue. Its lead asset, azetukalner, posted positive Phase 3 data in focal onset seizures, and Xenon submitted a New Drug Application to the FDA in September 2026, modeling a standard review of about 12 months.

What is azetukalner?

+

Azetukalner (formerly XEN1101) is Xenon's lead drug candidate, a potent KV7 potassium channel opener. If approved, it would be the only channel opener of its kind among antiseizure medications, and it is also being studied in depression and bipolar depression.

Why does XENE lose money every quarter?

+

As a clinical-stage biotech with no approved product, Xenon spends heavily on Phase 3 trials, regulatory work, and commercial preparation while generating little to no revenue. It reported a net loss of about $102 million in the first quarter of 2026 and about $111 million in the second quarter and about $110 million in the third quarter, which is typical for a pre-commercial drug developer.

How much cash does Xenon have?

+

After an equity raise of about $837.6 million, Xenon reported roughly $1.34 billion in cash and marketable securities. Management says its cash funds operations into 2029, covering the azetukalner filing, ongoing trials, and an early commercial build-out. Yahoo Finance's cash figure at September 30, 2026, which may not include longer-dated securities, is about $951 million, against about $6 million of debt, and the trailing net loss is about $429 million.

What are the main risks with XENE?

+

The biggest risk is binary dependence on azetukalner: a review delay, FDA setback, or weak data in additional indications could sharply cut the stock. Even with approval, the drug enters a crowded market of generics and branded competitors, and the company keeps posting large losses. In September 2026 two psychiatry trials were paused over tolerability, a reminder that side effects can limit the drug's reach.

How can I invest in XENE with a thesis-based approach?

+

With Walnut you can add XENE to a thematic basket, for example a novel-CNS or clinical-stage biotech theme, set a target weight, connect your brokerage, and place orders that bring the basket toward those targets. Walnut helps you track the position against your stated thesis rather than recommending the stock.

Why did Xenon pause its depression and bipolar trials?

+

In September 2026, after discussion with the data safety monitoring board, Xenon paused the X-NOVA3 major depressive disorder study and the X-CEED bipolar depression study to assess whether changing dose escalation could improve tolerability in psychiatry patients. The events under review were mainly dizziness and somnolence, plus less common effects such as confusion and word-finding problems; serious adverse events were described as rare. The X-NOVA2 depression study continues, with data expected in the first quarter of 2027, and the epilepsy program was not changed.

How has XENE stock performed in 2026?

+

As of November 20, 2026 XENE closed near $37.23, down about 16% year to date, about 38% over three months and about 7% over the past year, though up about 5% over the past month, within a 52-week range of roughly $33.38 to $72.66. Most of the drop followed the September 2026 psychiatry trial pause. The 16 analysts tracked had a mean price target near $72 and a strong-buy consensus. Walnut is not an investment adviser, and these are descriptions of past moves.

How did Xenon do in its latest quarter?

+

For the third quarter of 2026 (ended September 30), Xenon reported no product revenue and a net loss of about $110 million, or $1.11 per share, slightly narrower than the roughly $1.15 loss analysts expected. That followed a first-quarter loss of $1.17 per share against a $1.20 estimate. Consensus for the fourth quarter is a loss of about $1.14 per share, and the main events ahead are the FDA review of azetukalner and the X-NOVA2 depression readout expected in the first quarter of 2027.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Xenon Pharmaceuticals Inc.'s investor relations page or your broker before making investment decisions.